SCHEMBL26089326

SCHEMBL26089326

CCOC(=O)c1c(O)c2c(n(C)c1=O)CCC(C)(C)C2

nearest known ligand 0.46

Predicted protein targets (top 17)

geneUniProtsupporting neighboursconfidence
▸ ALDH1A1 P00352 7/20 0.46
▸ KDM4E B2RXH2 5/20 0.46
▸ LMNA P02545 3/20 0.41
▸ KMT2A Q03164 2/20 0.37
▸ RECQL P46063 2/20 0.36
▸ TSHR P16473 1/20 0.36
▸ HTT P42858 1/20 0.36
▸ SMN1; SMN2 Q16637 1/20 0.36
▸ MAPT P10636 3/20 0.35
▸ USP2 O75604 1/20 0.35
▸ GAA P10253 1/20 0.35
▸ PKM P14618 1/20 0.35
▸ CYP1A2 P05177 1/20 0.34
▸ MEN1 O00255 1/20 0.34
▸ POLB P06746 1/20 0.34
▸ PABPC1 P11940 1/20 0.34
▸ HSD17B10 Q99714 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL26089216 0.77 ALDH1A1 (0.48) ALDH1A1KDM4ELMNAKMT2ARECQL
SCHEMBL26089094 0.73 MAPT (0.44) ALDH1A1KDM4ELMNAKMT2ATSHR
SCHEMBL29284700 0.71 ALDH1A1 (0.47) ALDH1A1KDM4ELMNAKMT2ARECQL
SCHEMBL26419161 0.71 ALDH1A1 (0.47) ALDH1A1KDM4ELMNAKMT2ARECQL
SCHEMBL26088630 0.71 ALDH1A1 (0.47) ALDH1A1KDM4ELMNAKMT2ARECQL
SCHEMBL26086567 0.70 LMNA (0.44) ALDH1A1KDM4ELMNAKMT2AMAPT
SCHEMBL1399942 0.67 ALDH1A1 (0.55) ALDH1A1KDM4ELMNAKMT2ARECQL
SCHEMBL1401174 0.67 ALDH1A1 (0.55) ALDH1A1KDM4ELMNAKMT2ARECQL
SCHEMBL2498218 0.67 ALDH1A1 (0.51) ALDH1A1KDM4ELMNAKMT2ARECQL
SCHEMBL4497673 0.67 ALDH1A1 (0.57) ALDH1A1KDM4ELMNAKMT2ARECQL

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-12037322-B2 AHR agonists ELI LILLY AND COMPANY (US) 2024-07-16 — — US disclosed
US-12037322-B2 AHR agonists ELI LILLY AND COMPANY (US) 2024-07-16 — — US disclosed
US-20230127797-A1 AHR AGONISTS ELI LILLY AND COMPANY 2023-04-27 — — US disclosed
US-20230127797-A1 AHR AGONISTS ELI LILLY AND COMPANY 2023-04-27 — — US disclosed
US-20230127797-A1 AHR AGONISTS ELI LILLY AND COMPANY 2023-04-27 — — US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-12037322-B2 AHR agonists AHR, ARNT, RORC ALDH1A1 724/4885KDM4E 1656/4885LMNA 4176/4885
US-20230127797-A1 AHR AGONISTS AHR, ARNT, RORC ALDH1A1 724/4885KDM4E 1656/4885LMNA 4176/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.

Send feedback